Vasomune Therapeutics to Present on Vascular Leak in Combat-Relevant Injury at the 2026 Military Health System Research Symposium
Dr. Harold Kim will discuss Pegevongitide (AV-001), Vasomune's lead candidate targeting vascular leak, an underlying pathology in injury and illness across casualty care
Vasomune Therapeutics, Inc. ("Vasomune"), a clinical-stage biopharmaceutical company developing therapies that target vascular leak, today announced that Dr. Harold Kim, Chief Scientific Officer, will present at the 2026 Military Health System Research Symposium (MHSRS), taking place August 3–6, 2026, at the Gaylord Palms Resort and Convention Center in Kissimmee, Florida. MHSRS is the United States Department of War’s premier scientific meeting focused on addressing medical needs of military service personnel, bringing together military medical providers, scientists, academia, and industry to advance research across combat casualty care and military operational medicine.
Date: Tuesday, August 4, 2026
Time: 0800–1000 am EST, Hemorrhage Control & Vascular Dysfunction breakout session
